Research presented at the ASCO Annual Meeting 2025 highlighted new potential standards of care and other advances in breast cancer.

In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses primary results from ASCENT-04 evaluating sacituzumab govitecan plus pembrolizumab in metastatic ...

Dr Heather McArthur describes how ASCO 2025 showcased new standards of care in triple-negative and HER2-positive settings.

These four BofA Securities Growth 10 stocks come with reliable dividends and are are timely ideas for growth and income ...

EAU guidelines offer updated guidance on diagnosis, treatment, & follow-up of patients with metastatic & muscle-invasive ...

Ovarian cancer remains a significant global health challenge, often diagnosed at an advanced stage due to non-specific ...

focusing on the efficacy of BAVENCIO in combination with the anti-Trop-2 ADC sacituzumab govitecan (Trodelvy ®, Gilead Sciences) for patients with advanced urothelial carcinoma (UC) who are ...

It is also the second TROP2-targeting ADC to reach the EU market after Gilead Sciences' Trodelvy (sacituzumab govitecan), which was approved for a similar HR-positive, HER2-negative breast cancer ...

Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, getting a green light in China for sacituzumab tirumotecan (sac-TMT).